219 related articles for article (PubMed ID: 12843145)
1. Phantoms in the assay tube: heterophile antibody interferences in serum thyroglobulin assays.
Preissner CM; O'Kane DJ; Singh RJ; Morris JC; Grebe SK
J Clin Endocrinol Metab; 2003 Jul; 88(7):3069-74. PubMed ID: 12843145
[TBL] [Abstract][Full Text] [Related]
2. Heterophile antibodies may falsely increase or decrease thyroglobulin measurement in patients with differentiated thyroid carcinoma.
Giovanella L; Keller F; Ceriani L; Tozzoli R
Clin Chem Lab Med; 2009; 47(8):952-4. PubMed ID: 19589101
[TBL] [Abstract][Full Text] [Related]
3. Heterophile antibodies rarely influence the measurement of thyroglobulin and thyroglobulin antibodies in differentiated thyroid cancer patients.
Verburg FA; Wäschle K; Reiners C; Giovanella L; Lentjes EG
Horm Metab Res; 2010 Sep; 42(10):736-9. PubMed ID: 20486066
[TBL] [Abstract][Full Text] [Related]
4. Serum thyroglobulin in the monitoring of differentiated thyroid cancer.
Evans C; Tennant S; Perros P
Scand J Clin Lab Invest Suppl; 2016; 245():S119-23. PubMed ID: 27542000
[TBL] [Abstract][Full Text] [Related]
5. Spurious increase in serum chromogranin A: the role of heterophilic antibodies.
Giovanella L; Ceriani L
Clin Chem Lab Med; 2010 Oct; 48(10):1497-9. PubMed ID: 20666696
[TBL] [Abstract][Full Text] [Related]
6. Current thyroglobulin autoantibody (TgAb) assays often fail to detect interfering TgAb that can result in the reporting of falsely low/undetectable serum Tg IMA values for patients with differentiated thyroid cancer.
Spencer C; Petrovic I; Fatemi S
J Clin Endocrinol Metab; 2011 May; 96(5):1283-91. PubMed ID: 21325460
[TBL] [Abstract][Full Text] [Related]
7. Thyroglobulin (Tg) recovery testing with quantitative Tg antibody measurement for determining interference in serum Tg assays in differentiated thyroid carcinoma.
Persoon AC; Links TP; Wilde J; Sluiter WJ; Wolffenbuttel BH; van den Ouweland JM
Clin Chem; 2006 Jun; 52(6):1196-9. PubMed ID: 16574765
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the BRAHMS Kryptor(®) thyroglobulin minirecovery test in patients with differentiated thyroid carcinoma.
Giovanella L; Imperiali M; Verburg FA; Ceriani L
Clin Chem Lab Med; 2013 Feb; 51(2):449-53. PubMed ID: 23095203
[TBL] [Abstract][Full Text] [Related]
9. Undetectable serum thyroglobulin due to negative interference of heterophile antibodies in relapsing thyroid carcinoma.
Giovanella L; Ghelfo A
Clin Chem; 2007 Oct; 53(10):1871-2. PubMed ID: 17885144
[No Abstract] [Full Text] [Related]
10. Comparison of thyroglobulin antibody interference in first- and second-generation thyroglobulin immunoassays.
Giovanella L; Ceriani L
Clin Chem Lab Med; 2011 Jun; 49(6):1025-7. PubMed ID: 21391869
[TBL] [Abstract][Full Text] [Related]
11. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation?
Mazzaferri EL; Kloos RT
J Clin Endocrinol Metab; 2002 Apr; 87(4):1490-8. PubMed ID: 11932270
[TBL] [Abstract][Full Text] [Related]
12. Thyroglobulin measurement in the management of patients with differentiated thyroid cancer.
Algeciras-Schimnich A
Crit Rev Clin Lab Sci; 2018 May; 55(3):205-218. PubMed ID: 29546779
[TBL] [Abstract][Full Text] [Related]
13. Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma.
Spencer CA; Takeuchi M; Kazarosyan M; Wang CC; Guttler RB; Singer PA; Fatemi S; LoPresti JS; Nicoloff JT
J Clin Endocrinol Metab; 1998 Apr; 83(4):1121-7. PubMed ID: 9543128
[TBL] [Abstract][Full Text] [Related]
14. Concordance between thyroglobulin antibody assays.
Taylor KP; Parkington D; Bradbury S; Simpson HL; Jefferies SJ; Halsall DJ
Ann Clin Biochem; 2011 Jul; 48(Pt 4):367-9. PubMed ID: 21502198
[TBL] [Abstract][Full Text] [Related]
15. Assay of thyroglobulin in serum with thyroglobulin autoantibodies: an unobtainable goal?
Mariotti S; Barbesino G; Caturegli P; Marinó M; Manetti L; Pacini F; Centoni R; Pinchera A
J Clin Endocrinol Metab; 1995 Feb; 80(2):468-72. PubMed ID: 7852506
[TBL] [Abstract][Full Text] [Related]
16. Falsely elevated thyroglobulin and calcitonin due to rheumatoid factor in non-relapsing thyroid carcinoma: A case report.
Lupoli GA; Barba L; Liotti A; La Civita E; Lupoli R; Riccio E; Portella G; Formisano P; Beguinot F; Terracciano D
Medicine (Baltimore); 2019 Feb; 98(5):e14178. PubMed ID: 30702570
[TBL] [Abstract][Full Text] [Related]
17. Clinical impact of thyroglobulin (Tg) and Tg autoantibody method differences on the management of patients with differentiated thyroid carcinomas.
Spencer CA; Bergoglio LM; Kazarosyan M; Fatemi S; LoPresti JS
J Clin Endocrinol Metab; 2005 Oct; 90(10):5566-75. PubMed ID: 15985472
[TBL] [Abstract][Full Text] [Related]
18. Does a highly sensitive thyroglobulin (Tg) assay change the clinical management of low-risk patients with thyroid cancer with Tg on T4 < 1 ng/ml determined by traditional assays?
Rosario PW; Purisch S
Clin Endocrinol (Oxf); 2008 Mar; 68(3):338-42. PubMed ID: 17850379
[TBL] [Abstract][Full Text] [Related]
19. [Inappropriately undetectable thyroglobulin after exclusion of interference from thyroglobulin antibodies].
Munier P; Courtier F; Barrial K; Chikh K; Claustrat F; Le Bricon T; Bronner J; Sanabria E
Ann Biol Clin (Paris); 2011; 69(6):721-5. PubMed ID: 22123574
[TBL] [Abstract][Full Text] [Related]
20. Human chorionic gonadotropin suspected heterophile interference investigations in immunoassays: a recommended approach.
Jara-Aguirre JC; Baumann NA; Block DR; Algeciras-Schimnich A
Clin Chem Lab Med; 2019 Jul; 57(8):1192-1196. PubMed ID: 30753153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
